SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jonathan M. Traxler who wrote (472)8/18/1997 12:31:00 PM
From: David Bogdanoff   of 2173
 
The company has a potentially viable product, imo. It is not a product until the FDA (or some foreign country) approves it. It is difficult to assess what the prospects are without seeing the data. The clinical design for this drug is complicated because the disease process is complex and there are difficult to control sources of variability such as insulin intake. It appears from the wording of the press release that the clinical design was not robust and possibly failed to take into account extraneous sources of variability. Thus, a failed study does not equate to a failed drug.

If the drug is approved for even type 1 diabetes, then individual physicians can use it for off-label indications.

David
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News